Astria Therapeutics, Inc. Price, Forecast, Insider, Ratings, Fundamentals & Signals

Boston--(business wire)--astria therapeutics, inc. (nasdaq:atxs), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 9,000 shares of astria's common stock on april 1, 2024 under astria's 2022 inducement stock incentive plan. the 2022 inducement stock incentive plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of astria. the options were grant.

Boston, mass.--(business wire)--astria therapeutics, inc. (nasdaq:atxs), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced positive initial proof-of-concept results from the alpha-star phase 1b/2 clinical trial evaluating star-0215, a monoclonal antibody inhibitor of plasma kallikrein, in hereditary angioedema (hae) patients. initial results demonstrate a favorable safety and tolerability profile, mean monthly atta.

Boston--(business wire)--astria therapeutics, inc. (nasdaq:atxs), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, granted stock options to purchase 40,000 shares of astria's common stock on march 1, 2024 under astria's 2022 inducement stock incentive plan. the 2022 inducement stock incentive plan is used exclusively for the grant of equity awards to individuals who were not previously an employee of astria. the options were gran.

Boston--(business wire)--astria therapeutics, inc. (nasdaq:atxs), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today reported financial results for the fourth quarter and full year ended december 31, 2023, and provided a corporate update. “we have strong conviction in the potential for star-0215 to be the first-choice preventative therapy for hae,” said jill c. milne, chief executive officer at astria therapeutics. “our final.

Boston--(business wire)--astria therapeutics, inc. (nasdaq:atxs), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will present final star-0215 phase 1a healthy subject data at the upcoming american academy of allergy, asthma, & immunology (aaaai) annual meeting in washington, d.c. on february 23, 2024 at 3:15pm est. dr. william lumry, m.d., clinical professor of internal medicine at the university of.

As the year wound to a close, biotechs were in focus among the notable insider purchases.

Astria Therapeutics, Inc. (NASDAQ:ATXS ) Q3 2023 Earnings Conference Call November 13, 2023 8:30 AM ET Company Participants Elizabeth Higgins - Investor Relations Jill Milne - Co Founder, CEO, President & Director Noah Clauser - CFO & Treasurer Christopher Morabito - Chief Medical Officer Andrea Matthews - Chief Business Officer Andrew Komjathy - Chief Commercial Officer Conference Call Participants Eun Yang - Jefferies Sam Slutsky - LifeSci Capital Hartaj Singh - Oppenheimer Farhana Sakloth - Ladenburg Joe Pantginis - H.C. Wainwright Operator Good morning and welcome to the Astria Therapeutics Quarter Three 2023 Corporate Update.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company focused on developing life-changing therapies for allergic and immunological diseases, today announced that it will share new STAR-0215 data in a poster presentation at the upcoming American College of Allergy, Asthma, and Immunology (ACAAI) Annual Scientific Meeting in Anaheim, California on November 11, 2023 at 12:35pm PST. Dr. William Lumry, M.D., Clinical Professor of Internal Medicine at the Unive.

Astria Therapeutics has inked a worldwide exclusive license agreement with Ichnos Sciences for an OX40 portfolio targeting the potential treatment of atopic dermatitis (AD) and other allergic and immunological diseases. The focus of the collaboration centers on the development of the lead candidate, STAR-0310, a monoclonal antibody OX40 antagonist utilizing YTE half-life extension technology.

Astria Therapeutics (formerly Catabasis Pharma) has raised $100 million and acquired Quellis to develop STAR-0215, a plasma kallikrein inhibitor for hereditary angioedema (HAE). STAR-0215 has a longer half-life than existing HAE treatments, potentially offering a longer duration of action. The company is currently conducting a proof of concept trial for STAR-0215 in HAE patients, with results expected in mid-2024.

Astria (ATXS) gets FDA's fast track tag for its lead product candidate, STAR-0215, which is currently being evaluated in an early-mid-stage study to treat hereditary angioedema. The stock rises 5%.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (NASDAQ:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema (HAE) and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information regarding patient preference for efficacy measures when starting on or switching to a new preventative therapy at the upcoming 2023 US Hereditary Angioedema Association (HAEA) National Summit.

BOSTON--(BUSINESS WIRE)--Astria Therapeutics, Inc. (Nasdaq:ATXS), a biopharmaceutical company developing STAR-0215 for the treatment of hereditary angioedema and focused on life-changing therapies for rare and niche allergic and immunological diseases, today announced that it will present information on STAR-0215 and its development in two presentations at the 13th C1-Inhibitor Deficiency and Angioedema Workshop in Budapest, Hungary. Jou-Ku Chung, Vice President, Clinical Pharmacology and Trans.

Astria: Biotech To Watch With Proof Of Concept Established For HAE.

If you are looking for stocks that are well positioned to maintain their recent uptrend, Astria Therapeutics, Inc. (ATXS) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.